Fair Isaac Free cash flow increased by 28.3% to $223.09M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 206.4%, from $72.80M to $223.09M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 16.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $99.02M | $89.98M | $123.99M | $120.21M | $115.20M | $144.03M | $91.59M | $88.28M | $121.83M | $162.98M | $120.76M | $66.99M | $211.60M | $224.72M | $193.16M | $72.80M | $284.43M | $219.50M | $173.86M | $223.09M |
| QoQ Change | — | -9.1% | +37.8% | -3.0% | -4.2% | +25.0% | -36.4% | -3.6% | +38.0% | +33.8% | -25.9% | -44.5% | +215.9% | +6.2% | -14.0% | -62.3% | +290.7% | -22.8% | -20.8% | +28.3% |
| YoY Change | — | — | — | — | +16.3% | +60.1% | -26.1% | -26.6% | +5.8% | +13.2% | +31.8% | -24.1% | +73.7% | +37.9% | +60.0% | +8.7% | +34.4% | -2.3% | -10.0% | +206.4% |